ORMP ORAMED PHARMACEUTICALS INC Business Restructuring 8-K Filing 2025 - Payment Deferral Agreement Oramed Pharmaceuticals has agreed to defer a $6.25 million payment from Scilex Holding Company until January 31, 2025, in exchange for 5 million shares of common stock and a 4% royalty on certain product sales.Get access to all SEC 8-K filings of the ORAMED PHARMACEUTICALS INC